This shows that SAMHD1 is a critical determinant of nelarabine efficacy in ALL and that low SAMHD1 levels critically contribute to the specific nelarabine sensitivity of T-ALL cells. The gene discussed is SAMHD1; the disease is acute lymphoblastic leukemia.